2Petrylak DP,Tangen CM,Hussain MH,et al.Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer[J].N Engl J Med,2004,351:1513-1520.
3de Bono JS,Oudard S,Ozguroglu M,et al.Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment:A randomized open label trial[J].Lancet,2010,376:1147-1154.
4Kelly WK,Halabi S,Carducci MA,et al.A randomized,double blind,placebo-controlled phase Ⅲ trial comparing docetaxel,prednisone,and placebo with docetaxel,prednisone,and bevacizumab in men with metastatic castration-resistant prostate cancer (MCRPC):survival results of CALGB 90401 (abstract)[J].J Clin Oncol,2010,28 (18s):LBA4511.
5Fizazi KS,Higano CS,Nelson JB,et,al.Phase Ⅲ,randomized,placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.a randomized,phase Ⅱ[J].J Clin Oncol,2013,31 (14):1740-1747.doi:10.1200/JCO.2012.46.4149.
6Kantoff PW,Schuetz TJ,Blumenstein BA,et al.Overall survival analysis of a Phase Ⅱ randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer[J].J Clin Oncol,2010,28:1099-1105.
7Madan RA,Mohebtash M,Arlen PM,et al.Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer:a phase 1 dose-escalation trial[J].Lancet Oncol,2012,13(5):501-508.Epub 2012 Feb 10.
8Howard I,Scher MD,Karim Fizazi MD,et al.Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy[J].N Engl J Med,2012,367 (13):1187-1197.Epub 2012 Aug 15.
9Ryan CJ,Shah S,Efstathiou E,et al.Phase Ⅱ Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response[J].Clin Cancer Res,201 1,17:4854-4861.
10MacVicar,Gary R,Hussain Maha HB.Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer[J].Current opinion in oncology,2013,25 (3):252-260.
